New drug aims to tame tumor-triggered low blood sugar in rare cancer patients
NCT ID NCT06881992
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called ersodetug for people whose tumors cause dangerously low blood sugar that standard treatments can't control. About 16 adults with insulin-producing tumors will receive the drug alongside their usual care. The main goal is to see if ersodetug reduces the need for intravenous sugar to keep blood sugar levels safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR HYPERINSULINISM (TUMOR HI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigative Site
RECRUITINGChicago, Illinois, 60637, United States
-
Investigative Site
NOT_YET_RECRUITINGBethesda, Maryland, 20892, United States
-
Investigative Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
Investigative Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Investigative Site
RECRUITINGNew York, New York, 10021, United States
-
Investigative Site
RECRUITINGCanton, Ohio, 44718, United States
-
Investigative Site
RECRUITINGPortland, Oregon, 97239, United States
-
Investigative Site
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Investigative Site
RECRUITINGClichy, Île-de-France Region, 92110, France
-
Investigative Site
RECRUITINGRotterdam, South Holland, 3015, Netherlands
-
Investigative Site
RECRUITINGBasel, Canton Basel-Stadt, CH-4001, Switzerland
-
Investigative Site
RECRUITINGSaint Johns Wood, London, NW3 2QG, United Kingdom
-
Investigative Site
RECRUITINGWithington, Manchester, M20 4BX, United Kingdom